All News
Bah Humbug Vitamin D (12.20.2024)
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.
Read Article
Abuse of the Safety-Net 340B Drug Programs
Dr. Madelaine Feldman has written an important commentary on the 340B Drug Pricing Program, a safety-net program that would allow vulnerable populations to receive expensive new therapies. But she points out that "this well-intentioned program has strayed from its original purpose", allowing certain hospitals and for-profit pharmacies to exploit the program.
Read Article
Biosimilars Do Impact Biologic Drug Costs
MedPage Today
Introduction of biosimilars for the rheumatology drug adalimumab, whose original branded version Humira has long been a blockbuster, appears to have led to a dramatic drop in net spending for these products -- even though biosimilars barely dented Humira prescription rates.
Read Article
ICYMI: Sex related differences in PsA
Different factors are known to influence disease characteristics and outcomes in psoriatic arthritis (PsA).
Read Article
Improvements in Pain and Fatigue in Bimekizumab
Dr. Philip Mease discusses abstract 2368, presented at the 2024 ACR Convergence meeting in Washington, DC.
https://t.co/ON09z9yTuJ https://t.co/650TUdHwYm
Dr. John Cush RheumNow ( View Tweet)
RheumNow Live 2025: Feb 8-9, Dallas, TX! 🔬 Don’t miss top experts on Psoriatic Disease:
➡️ A. Ogdie: Preventing PsA
➡️ A. Kavanaugh: Biologic Therapies
➡️ K. Gordon: Head-to-Head Studies
Register now!
https://t.co/9qnqtpkwpT https://t.co/95TGS56vyA
Links:
Dr. John Cush RheumNow ( View Tweet)
Palliative Care in Rheumatology
Dr. Jiha Lee talks with Dr. Shannon Herndon about abstracts 0204 and 1064, presented at the 2024 ACR Convergence meeting in Washington, DC.
https://t.co/fqx8wGLTqI https://t.co/5mwJx3ZN6u
Dr. John Cush RheumNow ( View Tweet)
95 IBD pts had Magnetic resonance enterography (MRE). While 6/95 (6.3%) developed IBD-arthritis (mean 11 mos), finding Sacroiliitison MRE did not increase this risk. IBD arthritis risk was linked to arthralgia (OR 84) & extraintestinal manifestations (OR 7.4)… https://t.co/NGWGKn75jG https://t.co/IqY6XHWqqy
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Sex related differences in PsA
Different factors are known to influence disease characteristics and outcomes in psoriatic arthritis (PsA). Recently, there is new evidence that sex-related differences play a role not only in disease manifestations but also in efficacy and… https://t.co/60vdbWLltB https://t.co/nY1CuJhKMb
Dr. John Cush RheumNow ( View Tweet)
RheumNow Live 2025: Feb 8-9, Dallas, TX! 🔬 Don’t miss top experts on Psoriatic Disease:
➡️ A. Ogdie: Preventing PsA
➡️ A. Kavanaugh: Biologic Therapies
➡️ K. Gordon: Head-to-Head Studies
Register now!
https://t.co/BTLmc8HSKY https://t.co/KVsLF3yOZx
Links:
Dr. John Cush RheumNow ( View Tweet)
Metanalysis of 41 studies, & 5343 AAV pts showed 55% (2890) had infection; 36% w/ severe infxn. This included PJP, aspergillosis, candidiasis, HZ, CMV, etc. Pulmonary most common. Risk factors included older, ESRD, DM, smoking, Renal or lung involvement https://t.co/4TtnP5wGc4 https://t.co/RatBXPUk7a
Links:
Dr. John Cush RheumNow ( View Tweet)
1st MTX use in 242 Italian pts w/ chronic inflam arthritis (54% RA, 33% PsA, 16% UA). Overall, survival of MTX at 24 months was 60%, (40% @48 mos, 20% @96 mos). MTX survival in RA & PsA equal, but superior to UA (undiff. arthritis) https://t.co/g4pZpVmTnM https://t.co/gcKWriqfhG
Dr. John Cush RheumNow ( View Tweet)
CorEvitas registry study of 1823 psoriatic arthritis pts found that 11.1% fulfilled the fibromyalgia definition and 20.6% fulfilled the widespread pain definition. Factors assoc w/ FM: female, depression, anxiety, impaired function, BMI & #of comorbidities.… https://t.co/nDk8hPTlAu https://t.co/jnO5MijoGJ
Dr. John Cush RheumNow ( View Tweet)
Sex Differences in Psoriatic Arthritis
Dr. Catherine Bakewell shared key takeaways from a session presented Sunday morning by Dr. Laura Coates and Dr. Lihi Eder, as well as abstract 1709.
https://t.co/eKAzPSDQLH https://t.co/ACYMgVSW89
Dr. John Cush RheumNow ( View Tweet)
Bimekizumab in PsA Showed Sustained Reductions in Disease Impact
Dr. Eric Dein talks with Dr. Ana-Marie Orbai about abstract 0600, Bimekizumab-Treated Patients with Active Psoriatic Arthritis Showed Sustained Reductions in Disease Impact Assessed by the Psoriatic Arthritis… https://t.co/HiqIly6Kii https://t.co/sFyqHE6ug1
Dr. John Cush RheumNow ( View Tweet)
CorEvitas registry study of 1823 psoriatic arthritis pts found that 11.1% fulfilled the fibromyalgia definition and 20.6% fulfilled the widespread pain definition. Factors assoc w/ FM: female, depression, anxiety, impaired function, BMI & #of comorbidities.… https://t.co/rBZwUxQ8yw https://t.co/W42YDBnDCa
Dr. John Cush RheumNow ( View Tweet)
Lancet forecasts that in Australia 5.4 million will have arthritis 2040, a 31% increase 4.1 mill in 2025. Included 3.2 w/ OA, ~750K w/ RA, & 8500 w/ JIA. OA incr in males from 6.3% to 7% (2040). & 10.8 to 12.2% in F. RA will grow from 1.56 to 1.75% in males and 2.6 to 2.9% in… https://t.co/6DM0ZLlZ05 https://t.co/djPP1cUDOI
Dr. John Cush RheumNow ( View Tweet)
BMJ has published an extensive, full read review of the Advances in the management of psoriatic arthritis in adults - by Drs. Gladman and Kharouf, (great read and reference!) https://t.co/4Bz3Vq93jH https://t.co/ZhwKZ4XmNy
Dr. John Cush RheumNow ( View Tweet)
Another Stelara (Ustekinumab) biosimilar was FDA approved on 12/1 -- called Yesintek for the treatment of Crohn’s, Ulcerative Colitis, Psoriasis & PsA. This makes 6 FDA approved biosimilars for ustekinumab.https://t.co/SMKx1LnBB1 https://t.co/96u5YuvyIf
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Improving the Value of Musculoskeletal Ultrasound in Rheumatology Care
MSUS has emerged as a powerful asset in rheumatology, providing a real-time, non-invasive, and cost-effective solution for diagnosing and managing inflammatory arthritis conditions such as RA and PsA.… https://t.co/94i7NZGSJH https://t.co/XiSLNaLuf9
Dr. John Cush RheumNow ( View Tweet)
